64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms : Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection. / Loft, Mathias; Carlsen, Esben Andreas; Johnbeck, Camilla Bardram; Johannesen, Helle Hjorth; Binderup, Tina; Pfeifer, Andreas; Mortensen, Jann; Oturai, Peter; Loft, Annika; Berthelsen, Anne Kiil; Langer, Seppo Wang; Knigge, Ulrich; Kjaer, Andreas.

In: The Journal of Nuclear Medicine, Vol. 62, No. 1, 2021, p. 73-80.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Loft, M, Carlsen, EA, Johnbeck, CB, Johannesen, HH, Binderup, T, Pfeifer, A, Mortensen, J, Oturai, P, Loft, A, Berthelsen, AK, Langer, SW, Knigge, U & Kjaer, A 2021, '64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection', The Journal of Nuclear Medicine, vol. 62, no. 1, pp. 73-80. https://doi.org/10.2967/jnumed.120.244509

APA

Loft, M., Carlsen, E. A., Johnbeck, C. B., Johannesen, H. H., Binderup, T., Pfeifer, A., Mortensen, J., Oturai, P., Loft, A., Berthelsen, A. K., Langer, S. W., Knigge, U., & Kjaer, A. (2021). 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection. The Journal of Nuclear Medicine, 62(1), 73-80. https://doi.org/10.2967/jnumed.120.244509

Vancouver

Loft M, Carlsen EA, Johnbeck CB, Johannesen HH, Binderup T, Pfeifer A et al. 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection. The Journal of Nuclear Medicine. 2021;62(1):73-80. https://doi.org/10.2967/jnumed.120.244509

Author

Loft, Mathias ; Carlsen, Esben Andreas ; Johnbeck, Camilla Bardram ; Johannesen, Helle Hjorth ; Binderup, Tina ; Pfeifer, Andreas ; Mortensen, Jann ; Oturai, Peter ; Loft, Annika ; Berthelsen, Anne Kiil ; Langer, Seppo Wang ; Knigge, Ulrich ; Kjaer, Andreas. / 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms : Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection. In: The Journal of Nuclear Medicine. 2021 ; Vol. 62, No. 1. pp. 73-80.

Bibtex

@article{65de717c6cc24960885031a769459179,
title = "64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection",
abstract = "64Cu-DOTATATE PET/CT imaging 1 hour (h) post-injection (p.i.) is excellent for lesion detection in patients with neuroendocrine neoplasms (NEN). We hypothesized that the imaging time window can be extended up to 3h p.i. without significant differences in the number of lesions detected. Methods From a prospective study, we compared, on a head-to-head basis, sets of 64Cu-DOTATATE PET/CT images from 35 patients with NEN scanned 1h and 3h p.i. of 200 MBq 64Cu-DOTATATE. The number of lesions on both scans were counted and grouped according to organs or regions and compared with negative binomial regression. Discordant lesions (visible on the 1h or 3h p.i. 64Cu-DOTATATE PET but not the other) were considered true if found on simultaneous CT or later MR, CT or somatostatin receptor imaging. We measured lesion maximal standardized uptake values (SUVmax), reference normal organ or tissue mean SUV (SUVmean) and tumor-to-normal tissue ratios (TTN) calculated from SUVmax/ SUVmeanResults We found 822 concordant lesions (visible on both the 1h and 3h p.i. 64Cu-DOTATATE PET) and five discordant lesions of which four were considered true. One discordant case in one patient involved a discordant organ system (lymph node) detected on the 3h p.i. but not the 1h p.i. 64Cu-DOTATATE PET that did not alter the patient's disease stage (stage IV) because the patient had 11 additional concordant liver lesions. We found no significant differences between the number of lesions detected on the 1h and 3h p.i. 64Cu-DOTATATE PET. Throughout the 1-3 h p.i. imaging window, TTN (mean [95% confidence interval]) remained high in all key organs: Liver (1h p.i.: 12.6 [10.2; 14.9] , 3h p.i.: 11.0 [8.7; 13.4]), intestines (1h p.i.: 24.2 [14.9; 33.4], 3h p.i.: 28.2 [16.5; 40.0]), pancreas (1h p.i.: 42.4 [12.3; 72.5], 3h p.i.: 41.1 [8.7; 73.4]) and bone (1h p.i.: 103.0 [38.6; 167.4], 3h p.i.: 124.2 [57.1; 191.2]). Conclusion The imaging time window of 64Cu-DOTATATE PET/CT of patients with NEN can be expanded from 1h p.i. to 1-3 hours p.i. without significant differences in the number of lesions detected.",
author = "Mathias Loft and Carlsen, {Esben Andreas} and Johnbeck, {Camilla Bardram} and Johannesen, {Helle Hjorth} and Tina Binderup and Andreas Pfeifer and Jann Mortensen and Peter Oturai and Annika Loft and Berthelsen, {Anne Kiil} and Langer, {Seppo Wang} and Ulrich Knigge and Andreas Kjaer",
note = "Copyright {\textcopyright} 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",
year = "2021",
doi = "10.2967/jnumed.120.244509",
language = "English",
volume = "62",
pages = "73--80",
journal = "The Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine",
number = "1",

}

RIS

TY - JOUR

T1 - 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms

T2 - Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection

AU - Loft, Mathias

AU - Carlsen, Esben Andreas

AU - Johnbeck, Camilla Bardram

AU - Johannesen, Helle Hjorth

AU - Binderup, Tina

AU - Pfeifer, Andreas

AU - Mortensen, Jann

AU - Oturai, Peter

AU - Loft, Annika

AU - Berthelsen, Anne Kiil

AU - Langer, Seppo Wang

AU - Knigge, Ulrich

AU - Kjaer, Andreas

N1 - Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PY - 2021

Y1 - 2021

N2 - 64Cu-DOTATATE PET/CT imaging 1 hour (h) post-injection (p.i.) is excellent for lesion detection in patients with neuroendocrine neoplasms (NEN). We hypothesized that the imaging time window can be extended up to 3h p.i. without significant differences in the number of lesions detected. Methods From a prospective study, we compared, on a head-to-head basis, sets of 64Cu-DOTATATE PET/CT images from 35 patients with NEN scanned 1h and 3h p.i. of 200 MBq 64Cu-DOTATATE. The number of lesions on both scans were counted and grouped according to organs or regions and compared with negative binomial regression. Discordant lesions (visible on the 1h or 3h p.i. 64Cu-DOTATATE PET but not the other) were considered true if found on simultaneous CT or later MR, CT or somatostatin receptor imaging. We measured lesion maximal standardized uptake values (SUVmax), reference normal organ or tissue mean SUV (SUVmean) and tumor-to-normal tissue ratios (TTN) calculated from SUVmax/ SUVmeanResults We found 822 concordant lesions (visible on both the 1h and 3h p.i. 64Cu-DOTATATE PET) and five discordant lesions of which four were considered true. One discordant case in one patient involved a discordant organ system (lymph node) detected on the 3h p.i. but not the 1h p.i. 64Cu-DOTATATE PET that did not alter the patient's disease stage (stage IV) because the patient had 11 additional concordant liver lesions. We found no significant differences between the number of lesions detected on the 1h and 3h p.i. 64Cu-DOTATATE PET. Throughout the 1-3 h p.i. imaging window, TTN (mean [95% confidence interval]) remained high in all key organs: Liver (1h p.i.: 12.6 [10.2; 14.9] , 3h p.i.: 11.0 [8.7; 13.4]), intestines (1h p.i.: 24.2 [14.9; 33.4], 3h p.i.: 28.2 [16.5; 40.0]), pancreas (1h p.i.: 42.4 [12.3; 72.5], 3h p.i.: 41.1 [8.7; 73.4]) and bone (1h p.i.: 103.0 [38.6; 167.4], 3h p.i.: 124.2 [57.1; 191.2]). Conclusion The imaging time window of 64Cu-DOTATATE PET/CT of patients with NEN can be expanded from 1h p.i. to 1-3 hours p.i. without significant differences in the number of lesions detected.

AB - 64Cu-DOTATATE PET/CT imaging 1 hour (h) post-injection (p.i.) is excellent for lesion detection in patients with neuroendocrine neoplasms (NEN). We hypothesized that the imaging time window can be extended up to 3h p.i. without significant differences in the number of lesions detected. Methods From a prospective study, we compared, on a head-to-head basis, sets of 64Cu-DOTATATE PET/CT images from 35 patients with NEN scanned 1h and 3h p.i. of 200 MBq 64Cu-DOTATATE. The number of lesions on both scans were counted and grouped according to organs or regions and compared with negative binomial regression. Discordant lesions (visible on the 1h or 3h p.i. 64Cu-DOTATATE PET but not the other) were considered true if found on simultaneous CT or later MR, CT or somatostatin receptor imaging. We measured lesion maximal standardized uptake values (SUVmax), reference normal organ or tissue mean SUV (SUVmean) and tumor-to-normal tissue ratios (TTN) calculated from SUVmax/ SUVmeanResults We found 822 concordant lesions (visible on both the 1h and 3h p.i. 64Cu-DOTATATE PET) and five discordant lesions of which four were considered true. One discordant case in one patient involved a discordant organ system (lymph node) detected on the 3h p.i. but not the 1h p.i. 64Cu-DOTATATE PET that did not alter the patient's disease stage (stage IV) because the patient had 11 additional concordant liver lesions. We found no significant differences between the number of lesions detected on the 1h and 3h p.i. 64Cu-DOTATATE PET. Throughout the 1-3 h p.i. imaging window, TTN (mean [95% confidence interval]) remained high in all key organs: Liver (1h p.i.: 12.6 [10.2; 14.9] , 3h p.i.: 11.0 [8.7; 13.4]), intestines (1h p.i.: 24.2 [14.9; 33.4], 3h p.i.: 28.2 [16.5; 40.0]), pancreas (1h p.i.: 42.4 [12.3; 72.5], 3h p.i.: 41.1 [8.7; 73.4]) and bone (1h p.i.: 103.0 [38.6; 167.4], 3h p.i.: 124.2 [57.1; 191.2]). Conclusion The imaging time window of 64Cu-DOTATATE PET/CT of patients with NEN can be expanded from 1h p.i. to 1-3 hours p.i. without significant differences in the number of lesions detected.

U2 - 10.2967/jnumed.120.244509

DO - 10.2967/jnumed.120.244509

M3 - Journal article

C2 - 32444370

VL - 62

SP - 73

EP - 80

JO - The Journal of Nuclear Medicine

JF - The Journal of Nuclear Medicine

SN - 0161-5505

IS - 1

ER -

ID: 247889708